Market: median 1d +0.0% · breadth 14.9% advancing across 188 names
Data as of — announcements 2026-07-29 · flow 2026-07-24 · prices 2026-07-28
New today: AAJ, AIS, ASN, CBE, CPN, EYE, G50, HVY, MGU, OD6, SGQ, SLM, WA1. New names versus yesterday's letter, so a continuing story doesn't read as fresh news.
Read these (6)
Today's announcements worth minutes, not seconds — triaged by deterministic rules (a raise, a result into live flow, quantified materiality). The LLM annotates; it never picks the bucket.
Aruma's maiden Phase 1 drilling at Tillex (Ontario, Canada) confirms a broad, high-grade copper–silver system with wide mineralized zones (59–89m) and exceptional sub-intervals (up to 5.36% Cu), supported by downhole EM evidence of continuity at depth and along strike. Phase 2 expansion drilling (3,600m) is underway, but the $0.82m cash balance indicators imminent funding pressure for exploration acceleration.
💰Phase 1 drilling (Tillex): 1,093m completed · Best copper intersection (TX26-004): 89m @ 2.04% Cu, 12.31 g/t Ag · Best sub-interval (TX26-002): 5.6m @ 5.36% Cu, 56.89 g/t Ag · Phase 2 program: 3,600m ongoing
Materiality: Tillex acquisition and Phase 1 drilling represent core strategic focus for a $6m market-cap explorer; discovery validates 2026 exploration thesis but insufficient cash on hand to fund Phase 2 without capital raise.
Priced in? Stock +6% over 5d into announcement; -6% over 20d suggests modest run-up; broad-based institutional/market maker inflows ($34k+ MM flow vs. minimal retail) indicate sector attention but market cap constraints limit leverage.
AIS delivered strong operational and financial results for FY26 with record cash generation (~A$285m EBITDA, +78% YoY) driven by higher production (+19% copper YoY) and commodity prices, while maintaining tight cost control. Early-stage works on the Constellation Project and a fourfold reserve increase at Tritton indicator medium-term growth optionality, with the Peel Mining acquisition (post-period) expanding the portfolio.
Materiality: EBITDA uplift of ~A$100m represents ~18% of current market cap; cash position of A$202m covers ~2.4 quarters of combined opex + capex at current run-rate and substantially de-risks near-term funding.
Priced in? Stock down 3% over 20d and 1% over 5d into announcement; no material run-up suggests market had modest expectations or sentiment remained cautious despite strong fundamentals.
ASN · $68M — Anson to Conduct Western Block Exploration at Yellow Cat
Anson plans a Western Block confirmatory drilling program at Yellow Cat to upgrade 1950s-era uranium/vanadium historical resource to modern JORC standards, betting on resurgent US domestic uranium policy demand. Historical grades are marginal to moderate (U3O8 0.27–0.68%, V2O5 0.09–0.77%), with drilling contingent on environmental clearance and BLM permits expected Q3 2026.
Materiality: Exploration program scope and timing disclosed; no capital raise amount or updated resource figures provided. Program cost not quantified; insufficient data to assess against $68m market cap or cash runway.
Priced in? Stock down 9% over 20 days and 2% over 5 days into announcement; modest negative momentum suggests no run-up; incremental exploration news with permitting risk may have limited immediate price impact.
CBE has successfully transitioned Sierra Atacama to a producing, cash-generative asset within weeks of taking operational control, posting its first consecutive positive operating-cash-flow months and securing A$120m in follow-on capital to accelerate production ramp and exploration. The company has also expanded its district footprint to 22,000+ hectares and negotiated a clear pathway to 75% ownership, materially de-risking the Chilean operation.
Materiality: A$90m raise (~30% of $296m market cap) announced post-quarter; US$9.4m debt reduction and first positive cash flow represent significant operational validation of the turnaround thesis.
Priced in? Stock down 27% over 20d and 8% over 5d into announcement; positive cash flow milestone and large capital raise likely not fully priced in given recent weakness.
CPN · $41M — High-Grade Tin at Kelpie including 3m @ 9.32% Sn
CPN has delivered exceptional high-grade tin extensions at Kelpie's newly discovered Errol's Zone, with 9.32% Sn peak grades and multiple intervals >1% Sn—well above the deposit's current 0.50% Sn resource average and outside the existing pit-constrained resource, positioning significant near-term resource growth. Mineralisation remains open down-plunge and at depths suitable for both open-pit expansion and potential future underground mining, underpinned by a validated discovery model using IP/gravity and soil geochemistry.
💰Best intercept (BRC061): 3m @ 9.32% Sn · Primary intersection (BRC061): 20m @ 1.79% Sn · Current Kelpie resource: 3.94Mt @ 0.50% Sn (19,300t Sn) · Peak single metre: 14.0% Sn (historical context: Dumbrell's averaged 6% Sn)
Materiality: Results are resource-extension material: Errol's Zone sits outside the 19,300t contained tin resource; at typical tin valuations (~US$30–35/kg), even a modest 5,000–10,000t incremental resource would represent ~A$7–14m gross in-situ value (~17–34% of A$41m market cap), before stripping and mining costs.
Priced in? Stock +35% over 20d into announcement; retraced -5% in final 5d, suggesting some profit-taking after sustained run-up; market may have front-run discovery narrative, but grade/intercept magnitude appears to exceed prior guidance and recent peer precedent.
Nova Eye Medical has achieved inflection to positive H2 EBITDA on 26% annual revenue growth, with US market momentum (USA +30% Q4, +33% July YoY) offsetting China weakness and reducing cash burn to A$0.2m/quarter. FY27 guidance targets US$26–31m sales and positive full-year EBITDA, supported by 4% penetration of ~32,500 monthly glaucoma procedures in the USA.
Materiality: FY26 revenue of A$34.6m (annualised ~0.94x current market cap of A$37m) and A$3.7m liquidity runway (9–10 months at Q4 burn rate) are material to a A$37m company approaching profitability; insufficient data on free float.
Priced in? Stock +14% over 20 days but -11% over 5 days into this; routine quarterly reporting with no major surprises vs May 2026 upgraded guidance; priced-in assessment inconclusive without pre-announcement run-up granularity.
Who bought and sold, by broker cohort, on a T+3 lag — spikes vs each stock's own baseline, multi-session streaks, and warnings where 'buying' is likely someone absorbing an exit.